APLM
Apollomics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
23.78
▲ 0.20 (0.87%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
22.93
Prev close
23.57
Day high
24.59
Day low
22.93
Volume
6.27K
Market cap
$70.45M
P/E (TTM)
—
52W range
3.66 – 42.12
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.63M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | CHEN YI-KUEI ALEX Chief Operating Officer |
BUY | 20.00K | $468.00K | Indirect |
| Aug 14, 26 | LIN PETER KUAN-HOW Chief Financial Officer |
BUY | 26.67K | $624.01K | Direct |
| Aug 14, 26 | CHEN HUNG-WEN Chief Executive Officer |
BUY | 536.67K | $12.56M | |
| Jun 15, 26 | LIN PETER KUAN-HOW Chief Financial Officer |
— | 10.00K | — | Direct |
| Jun 15, 26 | CHEN HUNG-WEN Chief Executive Officer |
— | 5.00K | — | Direct |
| Jun 15, 26 | TSAI HSIEN-SHU Director |
— | 500 | — | Direct |
| Jun 15, 26 | JAN CHEN-HUAN Director |
— | 500 | — | Direct |
| Jun 15, 26 | CHU YI-AN Director |
— | 500 | — | Direct |
| Jun 15, 26 | CHEN HONG - JUNG MOSES Director |
— | 500 | — | Direct |
| Jun 15, 26 | CHEN YI-KUEI ALEX Chief Operating Officer |
— | 5.00K | — | Direct |
| May 15, 26 | HUANG YA-CHI Director |
— | 500 | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHEN HONG - JUNG MOSES |
Director | 3.62K | Conversion of Exercise of derivative security |
CHEN HUNG-WEN |
Chief Executive Officer | — | Purchase |
CHEN YI-KUEI ALEX |
Chief Operating Officer | — | Purchase |
CHU YI-AN |
Director | 1.50K | Conversion of Exercise of derivative security |
HUANG YA-CHI |
Director | 1.00K | Conversion of Exercise of derivative security |
JAN CHEN-HUAN |
Director | 1.50K | Conversion of Exercise of derivative security |
LIN PETER KUAN-HOW |
Chief Financial Officer | 48.98K | Purchase |
TSAI HSIEN-SHU |
Director | 1.50K | Conversion of Exercise of derivative security |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+3.96%
+5.3%
1M
+28.99%
+25.3%
3M
+70.01%
+66.9%
6M
+22.06%
+11.0%
YTD
+30.13%
+17.8%
1Y
+342.31%
+322.3%
3Y
-95.16%
-169.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$70.45M
Enterprise value$50.79M
Revenue (TTM)$8.84M
Gross profit$8.84M
EBITDA$-9.09M
Net income$-10.94M
EPS (TTM)$-7.57
Free cash flow$-9.81M
Total cash$3.28M
Total debt$643.00K
Book value / share$-1.49
Shares outstanding2.90M
Float553.67K
Short % of float0.60%
Dividend yield—
Beta (5Y)1.45
Short interest
Shares short
6.73K
Prior 5.14K
Change vs prior
+30.9%
Shorts adding
% of float
0.60%
Normal
% of shares out
0.31%
Against total outstanding
Days to cover
0.3
Liquid
Float
553.67K
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E—
Forward P/E-37.43
PEG ratio—
Price / sales—
Price / book—
EV / revenue5.74
EV / EBITDA-5.59
Gross margin100.00%
Operating margin431.87%
Profit margin-123.72%
Return on equity-1305.37%
Return on assets-57.61%
Debt / equity—
Current ratio0.96
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $8.50M | $0 | $0 | $0 | — | — |
| Operating revenue | $8.50M | $0 | $0 | $0 | — | — |
| Research & development | $5.53M | $24.57M | $34.19M | $35.46M | — | -77.5% |
| Selling, general & admin | $12.44M | $17.77M | $20.64M | $9.95M | — | -30.0% |
| Total operating expense | $17.69M | $42.03M | $54.37M | $44.39M | — | -57.9% |
| Operating income | -$9.19M | -$42.03M | -$54.37M | -$44.39M | — | +78.1% |
| Net interest income | $87.00K | $301.00K | $603.00K | $338.00K | — | -71.1% |
| Pre-tax income | -$10.94M | -$53.60M | -$172.59M | -$240.81M | — | +79.6% |
| Tax provision | $3.00K | $259.00K | $10.00K | $1.00K | — | -98.8% |
| Net income | -$10.94M | -$53.86M | -$172.60M | -$240.81M | — | +79.7% |
| Net income to common | -$10.94M | -$53.86M | -$172.60M | -$240.81M | — | +79.7% |
| Basic EPS | — | -52.80 | -231.99 | -2.99 | -1.18 | — |
| Diluted EPS | — | -52.80 | -231.99 | -2.99 | -1.18 | — |
| EBIT | -$10.87M | -$53.42M | -$172.44M | -$240.72M | — | +79.6% |
| EBITDA | -$10.62M | -$53.06M | -$171.77M | -$239.94M | — | +80.0% |
| Basic shares | — | 1.02M | 744.00K | 80.45M | 80.45M | — |
| Diluted shares | — | 1.02M | 744.00K | 80.45M | 80.45M | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.28M | $9.77M | $32.06M | $32.67M | -66.5% |
| Cash & short-term investments | $3.28M | $9.77M | $37.82M | $54.61M | -66.5% |
| Accounts receivable | $2.31M | $0 | — | — | — |
| Total current assets | $6.05M | $10.27M | $39.92M | $55.79M | -41.1% |
| Property, plant & equipment | $580.00K | $1.02M | $586.00K | $1.48M | -43.1% |
| Goodwill & intangibles | $0 | $1.74M | $14.76M | $14.78M | -100.0% |
| Total assets | $6.71M | $13.10M | $55.39M | $76.47M | -48.7% |
| Total current liabilities | $6.33M | $7.40M | $13.56M | $12.36M | -14.5% |
| Current debt | — | — | $4.24M | — | — |
| Total debt | $643.00K | $966.00K | $4.66M | $991.00K | -33.4% |
| Total liabilities | $9.90M | $8.23M | $14.15M | $524.60M | +20.3% |
| Retained earnings | -$711.76M | -$700.82M | -$646.97M | -$474.60M | -1.6% |
| Shareholder equity | -$3.19M | $4.86M | $41.23M | -$448.12M | -165.5% |
| Working capital | -$275.00K | $2.87M | $26.37M | $43.43M | -109.6% |
| Net tangible assets | -$3.19M | $3.13M | $26.48M | -$462.90M | -202.0% |
| Shares issued | 2.15M | 1.10M | 894.96K | 80.45M | +94.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.94M | -$53.60M | -$172.59M | -$240.81M | — | +79.6% |
| Depreciation & amortisation | $255.00K | $361.00K | $669.00K | $775.00K | — | -29.4% |
| Stock-based compensation | -$979.00K | $10.93M | $12.69M | $3.58M | — | -109.0% |
| Change in working capital | -$380.00K | $1.04M | -$3.57M | $6.49M | — | -136.6% |
| Operating cash flow | -$10.37M | -$28.74M | -$43.21M | -$42.82M | — | +63.9% |
| Capital expenditure | — | -$24.00K | -$6.00K | -$367.00K | -$7.55M | — |
| Investing cash flow | $218.00K | $5.98M | $21.36M | $29.05M | — | -96.4% |
| Dividends paid | $0 | $0 | $0 | $0 | — | — |
| Financing cash flow | $3.68M | $468.00K | $21.23M | -$294.00K | — | +685.5% |
| Free cash flow | -$10.37M | -$28.77M | -$43.22M | -$43.19M | — | +64.0% |
| End cash position | $3.28M | $9.77M | $32.06M | $32.67M | — | -66.5% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $3.28M | $2.09M | $9.77M | +56.4% |
| Cash & short-term investments | $3.28M | $2.09M | $9.77M | +56.4% |
| Accounts receivable | $2.31M | $7.20M | $0 | -68.0% |
| Total current assets | $6.05M | $10.13M | $10.27M | -40.3% |
| Property, plant & equipment | $580.00K | $680.00K | $1.02M | -14.7% |
| Goodwill & intangibles | $0 | $228.00K | $1.74M | -100.0% |
| Total assets | $6.71M | $11.12M | $13.10M | -39.6% |
| Total current liabilities | $6.33M | $10.47M | $7.40M | -39.6% |
| Total debt | $643.00K | $744.00K | $966.00K | -13.6% |
| Total liabilities | $9.90M | $15.52M | $8.23M | -36.2% |
| Retained earnings | -$711.76M | -$713.36M | -$700.82M | +0.2% |
| Shareholder equity | -$3.19M | -$4.40M | $4.86M | +27.5% |
| Working capital | -$275.00K | -$343.00K | $2.87M | +19.8% |
| Net tangible assets | -$3.19M | -$4.63M | $3.13M | +31.1% |
| Shares issued | 2.15M | 1.10M | 1.10M | +94.6% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2024 | -18.00 | — | — |
| Mar 2024 | -17.00 | — | — |
| Dec 2023 | -15.00 | — | — |
| Sep 2023 | -16.00 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders74.12%
Held by institutions0.52%
Institutions holding5
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 8, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 1, 24 | EF Hutton | MAINTAINED | Buy | Buy |
| Apr 1, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 20, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 3, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 5, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 1, 23 | HC Wainwright & Co. | INITIATED | — | Buy |
| Apr 25, 23 | EF Hutton | INITIATED | — | Buy |
Moving averages & technicals
SMA 10
21.28
+11.73% from price
SMA 20
19.35
+25.69% from price
SMA 50
18.85
+29.08% from price
SMA 100
16.58
+43.41% from price
SMA 200
17.51
+38.93% from price
EMA 12
21.50
+10.58% from price
EMA 26
19.97
+19.06% from price
EMA 50
18.84
+26.18% from price
RSI (14)
70.0
Overbought
MACD (12,26,9)
1.53
Hist 0.71
ATR (14)
1.87
7.68% of price
Realised vol 30D
164.7%
Annualised
Bollinger upper
25.13
20, 2σ
Bollinger lower
13.58
20, 2σ
50 / 200 cross
Golden
18.85 vs 17.51
Trend bias
Above 200
+38.93%
Risk profile
Beta vs SPY
0.70
Less volatile than market
Correlation to SPY
0.06
Largely independent
Realised vol 30D
164.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-68.3%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
1.87
7.68% of price
Beta (reported)
1.45
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:100
Split dateNov 25, 2024
SEC filings
Additional Forms
D · 2026-08-19
Corporate Changes & Voting Matters
6-K · 2026-08-12
Corporate Changes & Voting Matters
6-K · 2026-07-21
Corporate Changes & Voting Matters
6-K · 2026-07-14
Corporate Changes & Voting Matters
6-K · 2026-06-24
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-28
Offering Registrations
F-3/A · 2026-05-15
Corporate Changes & Voting Matters
6-K · 2026-04-27
Headlines
Apollomics Insider Bought Shares Worth $7,550,004, According to a Recent SEC Filing
MT Newswires · 5d ago
Apollomics Announces $10 Million Private Placement Transaction
GlobeNewswire · 11d ago
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
GlobeNewswire · 41d ago
Apollomics Receives Nasdaq Deficiency Notice Over Market Value Requirement
MT Newswires · 59d ago
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
GlobeNewswire · 59d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.